| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
This compound has no biological target. It is used as a chemical reagent for acylation reactions. The imidazole acts as a leaving group, making the benzoyl carbonyl carbon highly electrophilic, allowing for the efficient acylation of amines, alcohols, and thiols. This property is utilized in laboratory synthesis, not in biological systems.
|
|---|---|
| ln Vitro |
No in vitro biological activity is applicable. N-Benzoylimidazole is not a drug and is not used in biological assays. Its "activity" is purely chemical: the ability to efficiently acylate nucleophiles. The reaction is typically carried out in anhydrous organic solvents, not in aqueous or biologically relevant conditions.
|
| ln Vivo |
No in vivo activity is applicable. N-Benzoylimidazole is a synthetic organic intermediate. If ingested or absorbed, it would likely be rapidly hydrolyzed to benzoic acid and imidazole. Benzoic acid is a common food preservative that is metabolized to hippuric acid and excreted. Imidazole is a moderately toxic heterocycle. The compound is not administered for any therapeutic purpose.
|
| Enzyme Assay |
N-Benzoylimidazole is a chemical reagent; it is not tested in biological assays. Its chemical reactivity can be characterized by its conversion to a known product. For example, the reaction of N-Benzoylimidazole with aniline to form benzanilide can be monitored by HPLC or TLC. The reaction typically proceeds in high yield under mild conditions (room temperature, in an inert solvent like dichloromethane).
|
| Cell Assay |
No cell-based protocol is applicable. N-Benzoylimidazole is not used in cell culture. The compound is moisture-sensitive and would rapidly hydrolyze in aqueous culture media, forming benzoic acid and imidazole. It would have no specific pharmacological effect.
|
| Animal Protocol |
No in vivo animal protocol is applicable. N-Benzoylimidazole is a chemical intermediate used for synthesis. If administered to animals as a test substance, it would likely be irritating to the skin, eyes, and gastrointestinal tract due to its ability to acylate biological nucleophiles. Such administration is not standard practice.
|
| ADME/Pharmacokinetics |
Not applicable; N-Benzoylimidazole is a synthetic reagent, not a drug candidate. Its stability is moisture-sensitive, and it is typically stored under nitrogen at 2-8degC. For a drug, absorption, distribution, and metabolism would be evaluated; for this chemical, these properties are not relevant.
|
| Toxicity/Toxicokinetics |
For N-Benzoylimidazole, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). The compound is moisture-sensitive and may decompose to release irritating gases. Standard precautions for handling acylating agents apply: use PPE (gloves, lab coat, goggles), work in a fume hood, avoid inhalation and skin contact. Store at 2-8degC under nitrogen.
|
| References | |
| Additional Infomation |
N-Benzoylimidazole (CAS# 10364-94-0) is a research-grade organic synthesis reagent. It is valued as a mild and selective acylating agent for introducing a benzoyl protecting group onto amines, alcohols, and thiols. It is not an FDA-approved drug. For research and industrial use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C10H8N2O
|
|---|---|
| Molecular Weight |
172.19
|
| Exact Mass |
172.064
|
| CAS # |
10364-94-0
|
| PubChem CID |
66319
|
| Appearance |
Liquid
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
187
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C(=O)N2C=CN=C2
|
| InChi Key |
JEGIFBGJZPYMJS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8N2O/c13-10(12-7-6-11-8-12)9-4-2-1-3-5-9/h1-8H
|
| Chemical Name |
imidazol-1-yl(phenyl)methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8075 mL | 29.0377 mL | 58.0754 mL | |
| 5 mM | 1.1615 mL | 5.8075 mL | 11.6151 mL | |
| 10 mM | 0.5808 mL | 2.9038 mL | 5.8075 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
